60
Participants
Start Date
March 24, 2019
Primary Completion Date
June 16, 2022
Study Completion Date
June 16, 2022
Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
0.9% Sodium-chloride
normal saline
National Neuroscience Institute, Singapore
Lead Sponsor
Collaborators (1)
AegisCN LLC
INDUSTRY
Singapore Clinical Research Institute
OTHER
National Neuroscience Institute
OTHER